These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1830653)

  • 1. [Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].
    Guerois C; Parquet A; Vicariot M; Lecoeur FF; Maisonneuve P; Courouce AM; Dubois F; Laurian Y
    Presse Med; 1991 Jun; 20(25):1163-6. PubMed ID: 1830653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
    Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
    Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of human viral disease transmission through plasma products.
    Heldebrant CM; Friedman AE; Fedor EJ
    Dev Biol Stand; 1987; 67():319-22. PubMed ID: 2440744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia.
    Mariani G; Di Paolantonio T; Baklaya R; Morfini M; Mannucci PM
    Transfusion; 1993 Oct; 33(10):814-8. PubMed ID: 8236421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(1):19-25. PubMed ID: 7796372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group.
    Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU; Purcell RH
    Ann Intern Med; 1994 Jan; 120(1):1-7. PubMed ID: 7504424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of plasma-derived clotting factor concentrates.
    Mannucci PM
    Baillieres Clin Haematol; 1996 Jun; 9(2):273-90. PubMed ID: 8800505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of plasma and/or factor VIII concentrates administration on platelet functions in patients with haemophilia A and von Willebrand's disease (author's transl)].
    Gamba G; Grignani G; Nicolini E; Ascari E
    Haematologica; 1975 Jun; 60(2):168-83. PubMed ID: 808449
    [No Abstract]   [Full Text] [Related]  

  • 15. Coagulation products and their uses.
    Shord SS; Lindley CM
    Am J Health Syst Pharm; 2000 Aug; 57(15):1403-17; quiz 1418-20. PubMed ID: 10938981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
    Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
    Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and problems in hemophilia and von Willebrand's disease.
    Abildgaard CF
    Adv Pediatr; 1984; 31():137-77. PubMed ID: 6440429
    [No Abstract]   [Full Text] [Related]  

  • 18. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate.
    Schimpf K; Brackmann HH; Kreuz W; Kraus B; Haschke F; Schramm W; Moesseler J; Auerswald G; Sutor AH; Koehler K
    N Engl J Med; 1989 Oct; 321(17):1148-52. PubMed ID: 2507917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates.
    Funk M; Ebener U; Kreuz W; Ehrenforth S
    Lancet; 1993 Oct; 342(8876):933-4. PubMed ID: 7692198
    [No Abstract]   [Full Text] [Related]  

  • 20. Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease.
    Kreuz W; Klarmann D; Auerswald G; Auberger K; Gürtler L; Rabenau H; Doerr WD
    Lancet; 1993 Feb; 341(8842):446. PubMed ID: 8094219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.